Raymond James Financial Inc. acquired a new stake in shares of REGENXBIO Inc. (NASDAQ:RGNX – Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the SEC.

In a report released today, Judah Frommer from Morgan Stanley maintained a Sell rating on Galapagos (GLPG – Research Report), with a price ...

Data from the first patients enrolled into Regenxbio's trial of its gene therapy for rare inherited disease mucopolysaccharidosis type I (MPS I) – also known as Hurler syndrome – has shown the ...

FDMT 4D Molecular Therapeutics, Inc.